Ekspresi Monosit Kemotatik Protein-1 (MCP-1) pada Endometriosis
Crosstabs Kel_Usia * Subyek Crosstabulation
Subyek Endometrium
Endometriosis normal Total Kel_Usia <30 tahun Count
15
9
24 % within Subyek 71,4% 42,9% 57,1% 30 - 40 tahun Count
6
12
18 % within Subyek 28,6% 57,1% 42,9%
Total Count
21
21
42 % within Subyek 100,0% 100,0% 100,0%
Crosstabs Paritas * Subyek Crosstabulation
Subyek Endometrium
Endometriosis normal Total Paritas Count
21
4
25 % within Subyek 100,0% 19,0% 59,5% 1 - 3 Count
15
15 % within Subyek ,0% 71,4% 37,5%
>3 Count
2
2 % within Subyek ,0% 9,6% 4,8%
Total Count
21
21
42 % within Subyek 100,0% 100,0% 100,0%
Crosstabs Chi-Square Tests Asymp. Sig. Exact Sig.
Value df (2-sided) (2-sided)
a
Pearson Chi-Square 42,000 3 ,000 ,000 Likelihood Ratio 58,224 3 ,000 ,000 Fisher's Exact Test 47,919 ,000
b
Linear-by-Linear 29,329 1 ,000 ,000 Association N of Valid Cases
42 a. 4 cells (50,0%) have expected count less than 5. The minimum expected count is 1,50.
b. The standardized statistic is -5,416.
Crosstabs Proporsi dari observer 1 * Subyek Crosstabulation
Subyek Endometrium
Endometriosis normal Total Proporsi dari observer 1 ,00 Count
21
21 % within Subyek ,0% 100,0% 50,0%
1,00 Count
9
9 % within Subyek 42,9% ,0% 21,4%
2,00 Count
1
1 % within Subyek 4,8% ,0% 2,4%
3,00 Count
11
11 % within Subyek 52,4% ,0% 26,2%
Total Count
21
21
42 % within Subyek 100,0% 100,0% 100,0%
Chi-Square Tests Asymp. Sig. Exact Sig.
Value df (2-sided) (2-sided)
a
Pearson Chi-Square 42,000 3 ,000 ,000 Likelihood Ratio 58,224 3 ,000 ,000 Fisher's Exact Test 48,766 ,000
b
Linear-by-Linear 28,676 1 ,000 ,000 Association N of Valid Cases
42 a. 4 cells (50,0%) have expected count less than 5. The minimum expected count is ,50.
b. The standardized statistic is -5,355.
Proporsi dari observer 1 * Proporsi dari obsrever 2 Crosstabulation
Proporsi dari obsrever 2 ,00 1,00 2,00 3,00 Total
Proporsi dari observer 1 ,00 Count
21
21 % within Proporsi dari 100,0% ,0% ,0% ,0% 50,0% obsrever 2
1,00 Count
7
2
9 % within Proporsi dari ,0% 100,0% 40,0% ,0% 21,4% obsrever 2
2,00 Count
1
1 % within Proporsi dari ,0% ,0% 20,0% ,0% 2,4% obsrever 2
3,00 Count
2
9
11 % within Proporsi dari ,0% ,0% 40,0% 100,0% 26,2% obsrever 2
Total Count
21
7
5
9
42 % within Proporsi dari 100,0% 100,0% 100,0% 100,0% 100,0% obsrever 2
Symmetric Measures
Value df Asymp. Sig.
44,4% 100,0% 54,5% 52,4% Total Count
9
1
11
21 % within Proporsi dari observer 1
100,0% 100,0% 100,0% 100,0%
Chi-Square Tests
(2-sided) Exact Sig.
6
(2-sided) Exact Sig.
(1-sided) Point Probability Pearson Chi-Square 3,809
a
4 ,433 ,480 Likelihood Ratio 4,819 4 ,306 ,517 Fisher's Exact Test 4,085 ,554 Linear-by-Linear Association
,081
b
1 ,776 ,904 ,472 ,156 N of Valid Cases
21 a. 8 cells (88,9%) have expected count less than 5. The minimum expected count is ,10.
11 % within Proporsi dari observer 1
1
Value Asymp. Std.
Stadium * Proporsi dari observer 1 Crosstabulation
Error
a
Approx. T
b Approx. Sig.
Measure of Agreement Kappa ,855 ,065 8,734 ,000 N of Valid Cases
42 a. Not assuming the null hypothesis.
b. Using the asymptotic standard error assuming the null hypothesis.
Proporsi dari observer 1 Total 1,00 2,00 3,00
4
Stadium 2,00 Count
2
2 % within Proporsi dari observer 1
,0% ,0% 18,2% 9,5% 3,00 Count
5
3
8 % within Proporsi dari observer 1
55,6% ,0% 27,3% 38,1% 4,00 Count
b. The standardized statistic is -,285.
HasilPemeriksaan MCP-1 No Nama No lab PA Usia Paritas DerajatNyeri Stad Endometriosis
4 Kista Endometriosis +3 +3
4 Kista Endometriosis +1 +2
13 Ny Y R/HS/62/13 27 thn P0A0 Berat
3 Kista Endometriosis +1 +1
14 Ny B R/HS/63/13 29 thn P0A0 Sedang
4 Kista Endometriosis +1 +1
15 Ny D R/HS/64/13 39 thn P0A0 Ringan
2 Kista Endometriosis +2 +2
16 Ny A R/HS/65/13 24 thn P0A0 Sedang
17 Ny E R/HS/66/13 33 thn P0A0 Sedang
3 Kista Endometriosis +1 +1
3 Kista Endometriosis +1 +1
18 Ny S R/HS/67/13 25 thn P0A0 Sedang
4 Kista Endometriosis +3 +3
19 Ny E R/HS/74/13 29 thn P0A0 Sedang
4 Kista Endometriosis +1 +1
20 Ny I R/HS/83/13 29 thn P0A0 Sedang
4 Endometriosis +2 +2
21 Ny N R/HS/96/13 19 thn P0A0 Sedang
2 Kista Endometriosis +2 +2 LaboratoriumPatologiAnatomi FK USU diketahui
12 Ny J R/HS/61/13 26 thn P0A0 Sedang
11 Ny L R/HS/33/13 24thn P0A0 Sedang
HistopatologiJaringan EkspresiMCP1 Intensity score Observer 1 Ekspresi MCP1
5 Ny S R/HS/12/13 20 thn P0A0 Ringan
Intensity score Observer 2
1 Ny N R/HS/03/13 31thn P0A0 Ringan
3 Kista Endometriosis +2 +2
2 Ny A R/HS/04/13 27 thn P0A0 Sedang
3 Kista Endometriosis +2 +2
3 Ny E R/HS/07/13 35thn P0A0 Sedang
4 Kista Endometriosis +2 +3
4 Ny I R/HS/09/13 32thn P0A0 Sedang
3 Endometriosis +1 +1
3 Endometriosis +1 +1
4 Kista Endometriosis +3 +3
6 Ny R R/HS/18/13 35thn P0A0 Ringan
4 Endometriosis +1 +1
7 Ny J R/HS/21/13 27thn P0A0 Sedang
4 Kista Endometriosis +2 +3
8 Ny W R/HS/23/13 20thn P0A0 Sedang
3 Kista Endometriosis +1 +1
9 Ny H R/HS/25/13 28thn P0A0 Sedang
4 Kista Endometriosis +1 +1
10 Ny N R/HS/29/13 26thn P0A0 Sedang
( drJessyChrestella, SpPA ) HasilPemeriksaan MCP-1 Universitas Sumatera Utara No Nama No lab PA Usia Paritas DerajatNyeri Stad Endometriosis HistopatologiJaringan Ekspresi MCP1 Proportion
Observer 1 Ekspresi MCP1 Proportion Observer 2
17 Ny E R/HS/66/13 33 thn P0A0 Sedang
13 Ny Y R/HS/62/13 27 thn P0A0 Berat
3 Kista Endometriosis +1 +2
14 Ny B R/HS/63/13 29 thn P0A0 Sedang
4 Kista Endometriosis +2 +3
15 Ny D R/HS/64/13 39 thn P0A0 Ringan
2 Kista Endometriosis +2 +3
16 Ny A R/HS/65/13 24 thn P0A0 Sedang
4 Kista Endometriosis +3 +3
3 Kista Endometriosis +1 +1
12 Ny J R/HS/61/13 26 thn P0A0 Sedang
18 Ny S R/HS/67/13 25 thn P0A0 Sedang
4 Kista Endometriosis +3 +3
19 Ny E R/HS/74/13 29 thn P0A0 Sedang
4 Kista Endometriosis +1 +1
20 Ny I R/HS/83/13 29 thn P0A0 Sedang
4 Endometriosis +3 +2
21 Ny N R/HS/96/13 19 thn P0A0 Sedang
2 Kista Endometriosis +3 +3 LaboratoriumPatologiAnatomi FK USU diketahui
( drJessyChrestella, SpPA ) HasilPemeriksaan MCP-1
4 Kista Endometriosis +1 +1
3 Kista Endometriosis +1 +3
1 Ny N R/HS/03/13 31 thn P0A0 Ringan
3 Endometriosis +1 +1
3 Kista Endometriosis +3 +3
2 Ny A R/HS/04/13 27 thn P0A0 Sedang
3 Kista Endometriosis +3 +2
3 Ny E R/HS/07/13 35 thn P0A0 Sedang
4 Kista Endometriosis +2 +3
4 Ny I R/HS/09/13 32 thn P0A0 Sedang
3 Endometriosis +2 +1
5 Ny S R/HS/12/13 20 thn P0A0 Ringan
6 Ny R R/HS/18/13 35 thn P0A0 Ringan
11 Ny L R/HS/33/13 24 thn P0A0 Sedang
4 Endometriosis +1 +2
7 Ny J R/HS/21/13 27 thn P0A0 Sedang
4 Kista Endometriosis +3 +3
8 Ny W R/HS/23/13 20 thn P0A0 Sedang
3 Kista Endometriosis +1 +1
9 Ny H R/HS/25/13 28 thn P0A0 Sedang
4 Kista Endometriosis +1 +1
10 Ny N R/HS/29/13 26 thn P0A0 Sedang
4 Kista Endometriosis +2 +2
No Nama No lab PA Usia Paritas DerajatNyeri Stad Histopatologi EkspresiMCP1 EkspresiMCP1
Universitas Sumatera UtaraEndometriosis Jaringan Intensity score Observer 1 Intensity score Observer 2
14 Ny D O/HG/21/13 27 thn P1A0 Endometrium Negatif Negatif
Ekspresi MCP1 Proportion Observer 1 Ekspresi MCP1
No Nama No lab PA Usia Paritas DerajatNyeri Stad Endometriosis Histopatologi Jaringan
( drJessyChrestella, SpPA ) HasilPemeriksaan MCP-1
21 Ny E O/HG/49/13 27 thn P0A0 Endometrium Negatif Negatif LaboratoriumPatologiAnatomi FK USU diketahui
20 Ny P O/HG/42/13 34 thn P0A0 Endometrium Negatif Negatif
19 Ny R O/HG/41/13 25 thn P0A0 Endometrium Negatif Negatif
18 Ny A O/HG/32/13 28 thn P0A0 Endometrium Negatif Negatif
17 Ny S O/HG/24/13 30 thn P3A1 Endometrium Negatif Negatif
16 Ny S O/HG/23/13 26 thn P3A0 Endometrium Negatif Negatif
15 Ny F O/HG/22/13 31 thn P2A0 Endometrium Negatif Negatif
13 Ny D O/HG/20/13 28 thn P3A2 Endometrium Negatif Negatif
1 Ny R O/HG/1/13 29 thn P3A0 Endometrium Negatif Negatif
12 Ny I O/HG/16/13 32 thn P1A0 Endometrium Negatif Negatif
11 Ny N O/HG/14/13 32 thn P2A1 Endometrium Negatif Negatif
10 Ny M O/HG/13/13 30 thn P4A0 Endometrium Negatif Negatif
9 Ny S O/HG/12/13 22 thn P1A0 Endometrium Negatif Negatif
8 Ny S O/HG/10/13 33 thn P1A0 Endometrium Negatif Negatif
7 Ny S O/HG/9/13 34 thn P4A2 Endometrium Negatif Negatif
6 Ny S O/HG/8/13 30 thn P1A1 Endometrium Negatif Negatif
5 Ny E O/HG/7/13 32 thn P2A1 Endometrium Negatif Negatif
4 Ny P O/HG/5/13 29 thn P2A0 Endometrium Negatif Negatif
3 Ny R O/HG/4/13 33 thn P1A0 Endometrium Negatif Negatif
2 Ny E O/HG/2/13 30 thn P1A0 Endometrium Negatif Negatif
Proportion Observer 2 Universitas Sumatera Utara
1 Ny R O/HG/1/13 29 thn P3A0 Endometrium
13 Ny D O/HG/20/13 28 thn P3A2 Endometrium
21 Ny E O/HG/49/13 27 thn P0A0 Endometrium LaboratoriumPatologiAnatomi FK USU diketahui
20 Ny P O/HG/42/13 34 thn P0A0 Endometrium
19 Ny R O/HG/41/13 25 thn P0A0 Endometrium
18 Ny A O/HG/32/13 28 thn P0A0 Endometrium
17 Ny S O/HG/24/13 30 thn P3A1 Endometrium
16 Ny S O/HG/23/13 26 thn P3A0 Endometrium
15 Ny F O/HG/22/13 31 thn P2A0 Endometrium
14 Ny D O/HG/21/13 27 thn P1A0 Endometrium
12 Ny I O/HG/16/13 32 thn P1A0 Endometrium
2 Ny E O/HG/2/13 30 thn P1A0 Endometrium
11 Ny N O/HG/14/13 32 thn P2A1 Endometrium
10 Ny M O/HG/13/13 30 thn P4A0 Endometrium
9 Ny S O/HG/12/13 22 thn P1A0 Endometrium
8 Ny S O/HG/10/13 33 thn P1A0 Endometrium
7 Ny S O/HG/9/13 34 thn P4A2 Endometrium
6 Ny S O/HG/8/13 30 thn P1A1 Endometrium
5 Ny E O/HG/7/13 32 thn P2A1 Endometrium
4 Ny P O/HG/5/13 29 thn P2A0 Endometrium
3 Ny R O/HG/4/13 33 thn P1A0 Endometrium
( drJessyChrestella, SpPA ) Universitas Sumatera Utara
SANTA CRUZ BIOTECHNOLOGY, INC.
PRODUCT
MCP-1 (5J): sc-32771 Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe
BACKGROUND
The monocyte chemotactic proteins, MCP-1, MCP-2 and MCP-3, form a sub- family of the C-C (or β) chemokines, which are characterized by a set of con- served adjacent cysteines. MCPs are produced by a variety of cells, including T lymphocytes, subsequent to their activation with cytokines such as IL-1, TNFα and IFN-γ. MCP-1 levels are increased during infection and inflamma- tion, which are both characterized by leukocyte infiltration. In vitro studies have shown that the MCP isoforms exhibit their chemotactic effects on dif- ferent subpopulations of lymphocytes. MCP-1 is a potent basophil activator but does not affect eosinophils, whereas MCP-2 stimulates both eosinophils and basophils. MCP-3 has been shown to have the broadest range of influ- ence, activating monocytes, dendritic cells, lymphocytes, natural killer cells, eosinophils, basophils and neutrophils. Two MCP-1 receptors that differ in their carboxy-termini have been identified.
REFERENCES
1. Charo, I.F., et al. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91: 2752-2756.
2. Taub, D.D., et al. 1995. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 95: 1370-1376.
Suitable for use as control antibody for MCP-1 siRNA (h): sc-43913, MCP-1 shRNA Plasmid (h): sc-43913-SH and MCP-1 shRNA (h) Lentiviral Particles: sc-43913-V. Molecular Weight of MCP-1: 12 kDa. Positive Controls: human PBL whole cell lysate.
MCP-1 (5J) is recommended for detection of MCP-1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- 1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).
APPLICATIONS
in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Available azide-free for neutralizing, sc-32771 L, 200 µg/0.1 ml.
1
Each vial contains 200 µg IgG
RECOMMENDED SECONDARY REAGENTS
CHROMOSOMAL LOCATION Genetic locus: CCL2 (human) mapping to 17q12. SOURCE
MCP-1 (5J) is a mouse monoclonal antibody raised against recombinant MCP-1 of human origin.
3. Weber, M., et al. 1995. Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3. J. Immunol.
Universitas Sumatera Utara
13 K - < MCP-1 MCP-1 (5J): sc-32771. Immunoperoxidase staining of formalin fixed, paraffin-embedded human upper stomach tissue showing cytoplasmic staining of glandular cells.
25 K -
31 K -
46 K -
84 K -
MCP-1 (5J): sc-32771. Western blot analysis of human recombinant MCP-1.
DATA RESEARCH USE For research use only, not for use in diagnostic procedures.
To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-mouse IgG-HRP: sc-2005 (dilution range: 1:2000-1:32,000) or Cruz Marker™ compatible goat anti- mouse IgG-HRP: sc-2031 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecip- itation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 4) Immuno- histochemistry: use ImmunoCruz™: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.
154: 4166-4172.
4. Combadiere, C., et al. 1995. Monocyte chemoattractant protein-3 is a functional ligand for C-C chemokine receptors 1 and 2B. J. Biol. Chem. 270: 29671-29675.
5. Proost, P., et al. 1996. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J. Leukoc. Biol. 59: 67-74.
6. Dubois, P.M., et al. 1996. Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid. J.
Immunol. 156: 1356-1361.
7. Beall, C.J., et al. 1996. Site-directed mutagenesis of monocyte chemo- attractant protein-1 identifies two regions of the polypeptide essential for biological activity. Biochem. J. 313: 633-640.
8. Kuna, P., et al. 1996. Chemokines in seasonal allergic rhinitis. J. Allergy Clin. Immunol. 97: 104-112.
STOR AGE
Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.
- 00800 4573 8000 49 6221 4503 0 www.scbt.com